PASSAGE BIO, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
PASSAGE BIO, INC. (PASG) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 662.62 thousand shares for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-09-03.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-09-03
- PASSAGE BIO, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 872.70K shares, a 13.63% increase year-over-year.
- PASSAGE BIO, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 768.05K shares, a 94.04% decline year-over-year.
- PASSAGE BIO, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 12.88M shares, a 13.73% decline year-over-year.
- PASSAGE BIO, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 14.93M shares, a 32.44% increase year-over-year.
- PASSAGE BIO, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 10.25M shares, a 19.08% decline from fiscal 2022.
- PASSAGE BIO, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 12.67M shares, a 30.04% increase from fiscal 2021.
- PASSAGE BIO, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2021 was 9.74M shares, a 40.52% increase from fiscal 2020.
- PASSAGE BIO, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2020 was 6.93M shares, a 77.11% decline from fiscal 2019.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 662.62K shares S-4/A · filed 2026-09-03 | |||||||
| 2026-03-31 | 872.70K shares S-4 · filed 2026-07-21 | |||||||
| 2025-12-31 | 709.67K shares S-4/A · filed 2026-09-03 | |||||||
| 2025-09-30 | 724.03K shares 10-Q · filed 2025-11-10 | |||||||
| 2025-06-30 | 780.45K shares S-4/A · filed 2026-09-03 | |||||||
| 2025-03-31 | 768.05K shares S-4 · filed 2026-07-21 | 15.36M shares 10-Q · filed 2025-05-13 | ||||||
| 2024-12-31 | 587.31K shares S-4/A · filed 2026-09-03 | 11.75M shares 10-K · filed 2025-03-04 | ||||||
| 2024-09-30 | 622.20K shares 10-Q · filed 2025-11-10 | 12.45M shares 10-Q · filed 2024-11-13 | ||||||
| 2024-06-30 | 641.76K shares 10-Q · filed 2025-08-12 | 12.84M shares 10-Q · filed 2024-08-08 | ||||||
| 2024-03-31 | 12.88M shares 10-Q · filed 2025-05-13 | |||||||
| 2023-12-31 | 10.25M shares 10-K · filed 2025-03-04 | |||||||
| 2023-09-30 | 11.50M shares 10-Q · filed 2024-11-13 | |||||||
| 2023-06-30 | 14.75M shares 10-Q · filed 2024-08-08 | |||||||
| 2023-03-31 | 14.93M shares 10-Q · filed 2024-05-14 | |||||||
| 2022-12-31 | 12.67M shares 10-K · filed 2024-03-04 | |||||||
| 2022-09-30 | 12.21M shares 10-Q · filed 2023-11-13 | |||||||
| 2022-06-30 | 12.44M shares 10-Q · filed 2023-08-07 | |||||||
| 2022-03-31 | 11.28M shares 10-Q · filed 2023-05-11 | |||||||
| 2021-12-31 | 9.74M shares 10-K · filed 2023-03-06 | |||||||
| 2021-09-30 | 9.87M shares 10-Q · filed 2022-11-10 | |||||||
| 2021-06-30 | 9.03M shares 10-Q · filed 2022-08-04 | |||||||
| 2021-03-31 | 8.91M shares 10-Q · filed 2022-05-16 | |||||||
| 2020-12-31 | 6.93M shares 10-K · filed 2022-03-03 | |||||||
| 2020-09-30 | 6.97M shares 10-Q · filed 2021-11-04 | |||||||
| 2020-06-30 | 6.77M shares 10-Q · filed 2021-08-05 | |||||||
| 2020-03-31 | 6.36M shares 10-Q · filed 2021-05-05 | |||||||
| 2019-12-31 | 30.28M shares 10-K · filed 2021-03-03 | |||||||
| 2019-09-30 | 28.41M shares 10-Q · filed 2020-11-10 | |||||||
| 2019-06-30 | 20.89M shares 10-Q · filed 2020-08-13 | |||||||
| 2019-03-31 | 20.22M shares 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |